Journal
JOURNAL OF NEUROLOGY
Volume 258, Issue 3, Pages 449-456Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-010-5777-z
Keywords
Clinical trial; Multiple sclerosis; MRI; Dimethyl fumarate; BG-12; Hypointense lesions
Categories
Funding
- Biogen Idec, Inc.
- Swiss MS Society
- Czech Ministry of Education [MSM 0021620849]
- Biogen Idec
- UK Department of Health's National Institute for Health Research Biomedical Research Center (UCLH/UCL Comprehensive Biomedical Research Trust)
- MS Society of Great Britain and Northern Ireland
- GlaxoSmithKline
- Novartis
- Acorda Therapeutics
- Actelion Pharmaceuticals
- Allozyne
- BaroFold
- Bayer Health Care
- BayerSchering Pharma
- Bayhill
- Boehringer-Ingelheim
- Eisai
- Elan
- Genmab
- Merck-Serono
- Medici-Nova
- Sanofi-Aventis
- Santhera Pharmaceuticals
- Shire
- Roche
- Teva
- UCB
- Wyeth
- Swiss National Research Foundation
- European Union
- Gianni Rubatto
- Roche Research Foundations
- BayerSchering
- Genzyme
- Actelion
- Antisense Therapeutics
- Bayer
- MSD
- Pfizer
- Schering AG
- NIHR UCLH Comprehensive Biomedical Research Centre
- MRC
- Wellcome Trust
Ask authors/readers for more resources
BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p < 0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available